PIETER CULLIS, Ph.D.
Chair & Co-Founder
Pieter Cullis provides strong leadership with an entrepreneurial drive and his scientific and commercialization track record of success.
Dr. Pieter Cullis is also the Director of the Life Sciences Institute (LSI), Professor of the Department of Biochemistry and Molecular Biology and Director of the NanoMedicines Research Group at the University of British Columbia.
He has been very active in the development of several biotechnology companies and is recognized as a remarkable researcher and innovator. His work has led to three drugs that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications and five more that have finished Phase I clinical studies.
Dr. Cullis and co-workers are the key figures for the fundamental advances in generating, loading and targeting liposomal nanoparticulate (LNP) systems for intravenous delivery of conventional and genetic drugs. His drug delivery systems have improved formulations of several cancer therapies as well as other drug agents. His lipid nanoparticles delivery system is a leading technology worldwide, enabling the therapeutic potential of siRNA.
Dr. Cullis has published over 300 scientific articles. He has also received many prestigious awards, including the B.C. Science Council Gold Medal for Health Sciences in 1991, the Alec D. Bangham Award for contributions to liposome science and technology in 2000 and the B.C. Biotechnology Association award for Innovation and Achievement in 2002. He was elected a Fellow of the Royal Society of Canada in 2004, received the Leadership Award of the Canadian Society of Pharmaceutical Scientists in 2010, was awarded the Prix Galien, Canada’s premier prize for achievements in pharmaceutical R&D, in 2011, and received the LifeSciences BC Milton Wong Award for Leadership in 2015.